Nick is an associate at Gladstone Place Partners. He has strong capital markets and financial communications background both from working in-house and in communications and IR consulting agencies.
At Gladstone, Nick has worked on a range of projects involving activism defense, M&A, and equity story development spanning multiple sectors and businesses. Most recently, he supported Diffusion Pharma in its successful proxy contest against activist LifeSci Capital, and supported the communications for Hillenbrand’s €572 million acquisition of LINXIS Group.
Prior to Gladstone, Nick consulted at leading IR agencies such as ICR and KCSA Strategic Communications as well as several boutique agencies. During his consultancy career, Nick developed investor communications plans for public companies and provided guidance on sensitive and high-impact activities such as major organizational changes, IPOs and various corporate developments. Prior to consultancy, Nick supported the investor relations program of Endo Pharmaceuticals, a small cap pharmaceutical manufacturer, through a litigation crisis. Before Endo, Nick provided shareholder surveillance services at Nasdaq for its Fortune 500 clients.
Nick holds a B.B.A. in Finance from Temple University.